Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allergan Inc announces U.S. FDA approval


Monday, 30 Jun 2014 08:10am EDT 

Allergan Inc:Receives approval from U.S. Food and Drug Administration (FDA) for OZURDEX(reg)(dexamethasone intravitreal implant) 0.7 mg as treatment option for diabetic macular edema (DME) in adult patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic). 

Company Quote

190.06
0.62 +0.33%
31 Oct 2014